Citations

Clear

6273 citation(s) found for "To, Andrew".

Retrograde Intramedullary Femoral Lengthening With Acute Deformity Correction in Children, Adolescents, and Young Adults
Wellings, Elizabeth P. , Funk, Cole , Georgiadis, Andrew G. , Wellings, Elizabeth P , Funk, Cole , Georgiadis, Andrew G , Dahl, Mark T.

Mayo Clinic

JBJS Open Access | November 14, 2025 | Volume: 10 | Issue: 4 | Pages: No page available

10.2106/jbjs.oa.25.00231 | PMID 41220603 Get It

Background: Acquired and congenital limb length discrepancies often coexist with deformities of the distal femur. Lengthening of the femur along its anatomic axis changes the limb's mechanical alignment. Angular correction and lengthening can be achieved at the same site if a retrograde lengthening nail is used with a specific preoperative planning method (“reverse planning”) which permits patient-specific selection of the final mechanical axis. Methods: A consecutive cohort series of children, adolescents, and young adults (mean 15.6 ± 4.8 years) undergoing retrograde implantable femoral lengthening between the years 2011 and 2024 were analyzed. Surgical details, lengthening parameters, Limb Lengthening and Reconstruction Society (LLRS)–AIM index, accuracy of final correction, and complications were reviewed and classified. Patients were eligible only if the distal femoral physis was closed. Results: Seventy-three lengthening were eligible in the study period. Average lengthening was 4.2 ± 1.4 cm (range 2.0-8.0 cm), and consolidation index was 39.4 ± 21.9 days/cm. Deformities and length discrepancies were moderately complex, with a mean LLRS AIM score of 6 (range 1-13). Complication rates were similar to previous reports of intramedullary femoral lengthening, comparable between congenital (12 of 31, 39%) and acquired etiologies (16 of 42, 38%). Preoperative coronal alignment ranged from 14° varus to 20° valgus, while final coronal alignment was 0.4° ± 3.4° of neutral (range 7° valgus to 13° varus). Coronal deformities up to 20° and sagittal deformities up to 23° were corrected acutely at the lengthening site. Conclusions: Retrograde intramedullary femoral lengthening with acute deformity correction at the same site is an alternative to antegrade lengthening with separate osteotomy of the distal femur in children and adolescents. The reverse planning method allows reproducible length and deformity correction at the same location. Specific intraoperative technical adjuncts are used to achieve and maintain the desired alignment. Level of Evidence: Diagnostic Level IV . See Instructions for Authors for a complete description of levels of evidence.
Staged Reconstruction Is Not Necessary Following Oncologic Resection of Superficial Myxofibrosarcoma
GARAYUA-CRUZ, LEILANI, Broida, Samuel E. , Sullivan, Mikaela H. , Folpe, Andrew L. , Xu‐Welliver, Meng , Lee, K.N. , Ho, Thanh P. , Okuno, Scott H. , Rose, Peter S. , Bakri, Karim , Moran, Steven L. , Houdek, Matthew T. , Xu-Welliver, Meng , Lee, Katie N., Ho, Thanh P , Okuno, Scott , Houdek, Matthew T , Broida, Samuel E , Siontis, Brittany L. , Robinson, Steven I.

Mayo Clinic

Cancers | November 13, 2025 | Volume: 17 | Issue: 22 | Pages: 3637

10.3390/cancers17223637 | PMID 41301004 Get It

Background: Myxofibrosarcomas are notoriously highly infiltrative soft-tissue sarcomas, making negative surgical margins difficult to obtain. Recently, vacuum-assisted closure (VAC) is used to delay wound closure until a negative margin has been achieved; however, this can delay care and increase costs. Our institution has historically performed single-stage resections with intraoperative frozen margin analysis and reconstruction in these patients. The purpose of this study is to report the outcomes of this technique. Methods: We reviewed 112 patients (62 males, mean age 70 ± 14 years) with superficial myxofibrosarcoma. Eighty-eight patients received preoperative radiation. All patients underwent surgical resection with intraoperative frozen margin analysis, and the planned reconstruction was performed in a single anesthetic. Results: The 10-year local recurrence-free survival was 90%; positive intraoperative frozen section (HR 7.44, p = 0.004) and final permanent margins (HR 8.53, p = 0.007) were associated with local recurrence. Intraoperative margins were negative in 103 (92%) of patients, 1 of which was positive on final permanent section. There were nine cases of microscopically positive margins, of which seven underwent immediate re-excision to a negative margin. The accuracy of frozen margin assessment for myxofibrosarcoma was between 92.92 and 98.23%. All patients underwent reconstruction at the time of resection, with 19% needing an additional procedure, most commonly due to a wound complication (12%). Conclusions: Multidisciplinary single-stage excision with intraoperative frozen margin assessment and soft-tissue reconstruction yields low rates of local recurrence in patients with superficial myxofibrosarcoma.
Recommendations for Studying In Situ Extracellular Vesicles From Solid Tissue
Crescitelli, Rossella , Hendrix, An , Hill, Andrew F. , Ikezu, Tsuneya , Levy, Efrat , Puig, Berta , Paolini, Lucia , Vella, Laura J. , Hill, Andrew F , Ikezu, Tsuneya , Puig, Berta , Paolini, Lucia , Huang, Yiyao , Hurwitz, Stephanie N.

Mayo Clinic

Journal of Extracellular Vesicles | November 12, 2025 | Volume: 14 | Issue: 11 | Pages: No page available

10.1002/jev2.70185 | PMID 41220186 Get It

ABSTRACT Solid tissue‐derived extracellular vesicles (ST‐EVs) are extracellular vesicles (EVs) separated directly from solid tissues of both vertebrates and invertebrates. ST‐EVs provide a physiologically relevant snapshot of tissue‐specific molecular dynamics and can be enriched directly in situ, from tissues in their natural state, preserving the native characteristics of ST‐EVs. However, their enrichment presents unique technical challenges compared to EVs derived from biofluids or cell culture media. The need for transparent reporting in ST‐EV research is crucial to enhance the reproducibility, comparability, and reliability of research findings. The Solid Tissue Task Force, part of the Scientific Reproducibility Subcommittee of International Society for Extracellular Vesicles, aims to recommend reporting parameters and identify outstanding questions related to the pre‐analytical and analytical handling of solid tissues, as well as ST‐EV separation and characterization. These steps are essential for advancing the understanding of the biological roles of ST‐EVs and their potential clinical applications.
Acute Effects of a Multi-Ingredient Preworkout Supplement on Peak Torque and Muscle Excitation During an Isokinetic Fatigue Protocol
Connors, Benjamin R., Camic, Clayton L., Jagim, Andrew R. , Hill, Christopher M. , Chomentowski, Peter J., Kowal, Rachel A., Leon, Matteo F. de , Jagim, Andrew R , Sebastião, Émerson

Mayo Clinic

Sports | November 11, 2025 | Volume: 13 | Issue: 11 | Pages: 404

10.3390/sports13110404 | PMID 41295787 Get It

The primary purpose of this study was to examine the acute effects of a multi-ingredient preworkout supplement (MIPS) on isometric, concentric, and eccentric peak torque and electromyographic (EMG) responses of the leg extensors during a fatiguing isokinetic protocol. Thirteen male subjects (mean age ± SD = 22.9 ± 2.2 years) were assigned in crossover fashion to ingest an MIPS or placebo before an isokinetic protocol that consisted of 30 maximal, concentric and eccentric muscle actions with EMG signals recorded from the vastus lateralis, rectus femoris, and vastus medialis muscles. Immediately before (PRE) and after (POST) the isokinetic fatigue protocol, subjects were assessed for isometric peak torque. The MIPS condition resulted in greater isometric (205 ± 48 vs. 185 ± 44 N·m, p = 0.04) and concentric (121 ± 34 vs. 103 ± 27 N·m, p = 0.015) torque values versus placebo (collapsed across time). For eccentric peak torque as well as EMG amplitude and frequency values, there were no significant (p > 0.05) interactions or main effects for each condition. These findings indicated that acute ingestion of the MIPS enhanced isometric and concentric peak torque of the leg extensors, which was not explained by changes in the EMG signal.
TMOD-26. EGFRvIII overexpression and loss of mouse specific CDKN2A in glial cells leads to spontaneous gliomagenesis in a novel mouse model
Singh, Olivia, Li, Mira , Ali, Hafsah, Wei, Qingxia , Patil, Vikas , Aldape, Kenneth , Gao, Andrew , Zadeh, Gelareh , Singh, Olivia , Voisin, Mathew , Karimi, Shirin , Wilson, Mark, Agnihotri, Sameer

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v479-v479

10.1093/neuonc/noaf201.1900 Get It

Abstract A new mouse model for the classical subtype of human glioblastoma (GBM) has been bred using Cre-mediated EGFRvIII overexpression and homozygous p19-ARF deletion, the mouse homolog of human p14ARF/CDKN2A, in GFAP expressing cells. Transgenic mice develop intraparenchymal and/or leptomeningeal brain lesions with some spinal cord invasion as early as 1 month old and 95% of mice die by 6 months due to hydrocephalus and/or paralysis. Mice with high grade tumors have worse survival and similar features to human classical GBM such as necrosis, high levels of mitosis and infiltration of tumor cells into normal brain. Immunohistochemical analysis confirms EGFRvIII overexpression and p19-ARF loss in Cre-expressing cells, along with patchy positive GFAP and high proliferation by Ki67. Bulk RNA sequencing reveals GEC3 tumors cluster closely with human classical GBM and have significant upregulation of downstream markers in the JAK/STAT and P13K/AKT pathways. Adherent and neurosphere primary culture of dissociated tumors indicate that tumor cells maintain EGFRvIII expression in culture and generate xenograft tumors by 3 weeks after intracranial injections into NODSCID mice. Xenograft tumors are reminiscent of the primary tumor, with similar histopathological features and immunohistochemical staining. Our spontaneous glioma model is a powerful tool for future studies focused on the role of the immune microenvironment on glioma recurrence and resistance.
TIP-26. A phase II study evaluating the safety, efficacy, and intracranial activity of tarlatamab in recurrent/refractory IDH -mutant gliomas (TARGID)
Wang, Xin , Bennett, Julie, Muniz, Thiago Pimentel , Fat, Mary Jane Lim, Gao, Andrew , Zadeh, Gelareh , Nassiri, Farshad , Chen, Eric X. , Mason, Warren , Bennett, Julie , Tsang, Derek S.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v426-v427

10.1093/neuonc/noaf201.1686 Get It

Abstract Recurrent or refractory IDH-mutant (mt) gliomas represent a population with significant unmet clinical need. The Notch ligand delta-like 3 (DLL3) is a tumor-associated antigen that is highly and homogeneously expressed in IDH-mt gliomas but absent in normal brain tissue, making it an attractive therapeutic target. Tarlatamab is a half-life extended bispecific T-cell engager that targets DLL3 and CD3 to redirect cytotoxic T cells toward DLL3-expressing tumor cells. Given the specific expression of DLL3 in IDH-mt gliomas and promising activity of tarlatamab in other DLL3-positive tumors, this study investigates the safety, efficacy, and intracranial activity of tarlatamab in this patient population. TARGID is an open-label, phase II trial enrolling adult patients with histologically confirmed IDH1 or IDH2-mt astrocytoma or oligodendroglioma following up to two prior lines of systemic therapies. The study comprises two cohorts. Cohort 1 (n=10) includes patients with resectable disease who will receive up to three cycles of tarlatamab prior to surgery; postoperative continuation is permitted. The primary endpoint for this cohort is the change in CD8+ T-cell infiltration in tumor tissue and blood. Cohort 2 (n=34) includes patients with unresectable disease and uses a Simon’s optimal two-stage design (H0: P ≤ 0.1 versus H1: P ≥ 0.25). In the 1st stage, 13 patients will be accrued. If 2 or more responses are observed, 21 additional patients will be enrolled. Tarlatamab is administered intravenously at 10 mg every two weeks, following a 1 mg priming dose on Cycle 1 Day 1. The primary endpoint is objective response rate by RANO 2.0. Exploratory endpoints include DLL3 expression, circulating biomarkers, and immune correlatives. The trial is currently in activation, with first patient enrollment anticipated in Q3 2025. The study is supported by the provision of study drug from Amgen as an investigator-initiated trial.
TMET-54. Rewiring of cortical glucose metabolism fuels human brain cancer growth
O’Brien, Alexandra, Bailleul, Justine , Zhou, Weihua , Xu, Jie , Lin, Angelica , Wilder-Romans, Kari , Korimerla, Navyateja , Feng, Jiane, Zhang, Li , Andren, Anthony , Tarnal, Vijay , Redic, Kimberly, Qi, Nathan , Fischer, J, Suresh, Krithika , Venneti, Sriram , Vlashi, Erina , Wahl, Daniel , Scott, Andrew J. , Mittal, Anjali , Meghdadi, Baharan , Palavalasa, Sravya , Achreja, Abhinav , Liang, Ningning , Kothari, Ayesha U. , Edwards, Donna , Wu, Zhe , Sajjakulnukit, Peter , Park, Junyoung O. , Hoeve, Johanna ten , Fischer, Joshua, Yang, Ethan , Regan, Michael S. , Stopka, Sylwia A. , Baquer, Gerard , Sarkaria, Jann N. , Lawrence, Theodore S. , Agar, Nathalie Y.R. , Lyssiotis, Costas A. , Al‐Holou, Wajd N. , Nagrath, Deepak

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v440-v441

10.1093/neuonc/noaf201.1745 Get It

Abstract The brain avidly consumes glucose to fuel neurophysiology. Cancers of the brain, such as glioblastoma (GBM), relinquish physiological integrity and gain the ability to proliferate and invade healthy tissue. How brain cancers rewire glucose utilization to drive aggressive growth remains elusive. Here, we infused 13C-labeled glucose into patients and mice with brain cancer, coupled with quantitative metabolic flux analysis, to map the fates of glucose-derived carbon in tumor vs. cortex. Through the first direct and comprehensive measurements of carbon and nitrogen labeling in both cortex and glioma tissues, we uncover profound metabolic transformations. In human cortex, glucose carbons fuel essential physiologic processes including TCA cycle oxidation and neurotransmitter synthesis. Conversely, gliomas downregulate these processes and scavenge alternative carbon sources such as amino acids from the environment, repurposing glucose-derived carbons to generate molecules needed for proliferation and invasion. Targeting this metabolic rewiring in mice through dietary amino acid modulation selectively alters GBM metabolism, slows tumor growth, and augments the efficacy of standard-of-care treatments. These findings illuminate how aggressive brain tumors exploit glucose to suppress normal physiological activity in favor of malignant expansion and offer potential therapeutic strategies to enhance treatment outcomes.
TMET-56. Targeting transsulfuration via suppression of thyroid hormone signaling: a modified phase 1/2 and pharmacodynamic trial of methimazole in patients with progressive WHO grade 4 gliomas
Ponti, András K. , Angelov, Lilyana , Barnett, Gene H. , Hage, Lea El , Grabowsky, Matthew, Hufsey, Rachel, Lobbous, Mina , Malkin, Mark G. , Mohammadi, Alireza M. , Silver, Daniel J. , Stevens, Glen , Torres-Trejo, Alejandro, Lathia, Justin D. , Peereboom, David M. , Yang, Kailin , Cordova, Christine , Dhawan, Andrew , Soni, Pranay , Hine, Christopher

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v441-v441

10.1093/neuonc/noaf201.1747 Get It

Abstract BACKGROUND Gaseous hydrogen sulfide (H2S), a by-product of cysteine metabolism, inhibits cancer cell behavior and growth in glioblastoma (GBM) models. H2S production capacity (HPC) is decreased in human GBM specimens compared to non-tumor controls. Thus, boosting HPC is a novel strategy for GBM treatment. Suppression of thyroid hormone signaling increases production of H2S. Hypothesis: methimazole-induced hypothyroidism will increase tumor HPC to enhance chemotherapy efficacy in GBM. GOAL Proof of concept that methimazole, by reducing thyroid hormone signaling, can increase HPC in patients with recurrent/progressive GBM (rGBM). PRIMARY ENDPOINTS 10% increase in HPC and a 1.5-fold increase in peripheral blood sulfhydration signaling. METHODS This window of opportunity trial evaluates safety, HPC in plasma and tumor, and efficacy of methimazole + chemotherapy in patients with rGBM. rGBM patients planned for a resection begin methimazole 15 mg/d 5-7 days pre-op with investigator’s choice chemotherapy added 10-28 days post-op. Patients receive combination until progression. Pre- and post-op plasma and resected tumor tissue are assayed for HPC and proteins relevant to H2S production. Key eligibility: rGBM for whom a clinically-indicated resection is planned; normal thyroid function with no history of thyroid dysfunction. Patients may have received unlimited prior regimens including bevacizumab. RESULTS To date 15 patients (8 male), median age 56 years, enrolled. The trial was amended to increase methimazole to 25 mg/d; 3 patients have received this dose. Median TSH rose from 1.3 mU/ml to 20.5 at cycle 6. Free T3 and T4 did not fall significantly. Median plasma HPC rose 3-fold while tumor HPC did not rise significantly. No treatment-related grade 3-5 toxicities. Efficacy: PFS6 – 15% and OS12 – 21%. CONCLUSIONS Induction of subclinical hypothyroidism is feasible and safe in rGBM with significant increases in plasma but not tumor HPC. Further tumor correlative data for the dose-escalated methimazole will be presented.
IMG-72. [68Ga]Ga-DOTA-TATE PET as imaging biomarker for response assessment and monitoring in patients receiving [177Lu]Lu-DOTA-TATE for advanced intracranial meningioma
Kurz, Sylvia C. , Zan, Elçin , Lobbous, Mina , Malkin, Mark G. , Miller, Alexandra , Zagzag, David , Golfinos, John G. , Friedman, Kent, Shepherd, Timothy M. , Peereboom, David M. , Cordova, Christine , Barbaro, Marissa , Dhawan, Andrew , Silverman, Joshua S. , Snuderl, Matija , Kondziolka, Douglas , Troxel, Andrea B. , Sulman, Erik P.

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v290-v290

10.1093/neuonc/noaf201.1151 Get It

Abstract BACKGROUND [68Ga]Ga-DOTA-TATE (68Ga-Dotatate) PET is a promising imaging modality for post-operative meningioma delineation and outcome assessments following stereotactic radiosurgery. However, its utility for response assessment following other meningioma therapies, including somatostatin receptor 2 (SSTR2) targeting [177Lu]Lu-DOTA-TATE (177Lu-Dotatate) therapy is insufficiently understood. Here we report the 68Ga-Dotatate PET results, prospectively obtained in patients with treatment-refractory meningioma who enrolled in a phase 2, open-label clinical trial (NCT03971461) evaluating the radiopharmaceutical 177Lu-Dotatate. METHODS Patients underwent 68Ga-Dotatate PET during screening and 24±2 weeks following treatment with 177Lu-Dotatate at 7.4 GBq (200 mCi) every 8 weeks for 4 doses. Up to 5 meningioma lesions per patient were assessed by gadolinium-enhanced T1 MRI and 68Ga-Dotatate PET using lesional Krenning score and lesional to superior sagittal sinus (SSS) maximum standardized uptake value (SUVmax) ratio (SUVR (lesion/SSS)). RESULTS Eight patients with 16 lesions were assessed. By RANO criteria, the best radiographic response was stable disease (SD) in 7 patients (14 lesions) and partial response (PR) in 1 patient (2 lesions). Krenning score was assessed in 14 lesions (Krenning 4/3/2/1 in 3/4/5/2 lesions). Following 177Lu-Dotatate, Krenning score was reduced by ≥1 point in 9 and remained stable in 5 lesions. SUVR (lesion/SSS) was evaluated in 16 lesions. Compared to baseline, SUVR (lesion/SSS) at 6 months was partially reduced (PR, ≥50%) in 2 lesions, minimally reduced (MR, <50% and ≥25%) in 3 lesions, and stable (SD, <25% reduction and <25% increase) in 11 lesions. CONCLUSIONS 68Ga-Dotatate PET is a promising imaging biomarker in patients with advanced meningioma. Treatment with 177Lu-Dotatate led to substantial reduction in SUVR (lesion/SSS) in a subset of patients. In contrast to other reports, 68Ga-Dotatate assessments were generally concordant with post-gad T1 based MRI assessments per RANO. Updated results in an expanded group of patients will be presented.
PTHP-11. Assessment of Molecular Tools in Pediatric, Adolescent and Young Adult Meningioma Highlights Unique Biology and Underscores the Need for Lifespan Precision in Neuro-Oncology
Yefet, Leo, Landry, Alexander , Wang, Justin Z. , Patil, Vikas , Ajisebutu, Andrew, Gui, Chloe , Aldape, Kenneth , Nassiri, Farshad , Zadeh, Gelareh , Yefet, Leo, Liu, Jeff , Ellenbogen, Yosef

Mayo Clinic

Neuro-Oncology | November 11, 2025 | Volume: 27 | Issue: Supplement_5 | Pages: v269-v269

10.1093/neuonc/noaf201.1068 Get It

Abstract Pediatric, adolescent and young adult patients (Ped/AYA; 0–39 years) with meningiomas are underrepresented in neuro-oncology research, despite meningiomas being the second most common primary brain tumor in this age group. While DNA methylation-based models have advanced classification and prognostication in adults, their utility in younger populations remains uncertain. To address this gap, we aimed to evaluate the performance of current DNA methylation-based classification and recurrence prediction models in Ped/AYA patients with meningiomas and identify age-associated molecular differences. As part of this study, we analyzed 1,568 meningioma samples with DNA methylation and clinical data, including subsets with whole-exome and RNA sequencing. Patients were grouped into Ped/AYA (≤39 years, n = 213) and adult (>39 years, n = 1,355) cohorts. We assessed classifier performance, performed subgroup-specific model retraining, and compared molecular profiles across age groups. Our results showed that molecular classification differed significantly between age groups, with Ped/AYA tumors less frequently belonging to the most aggressive Proliferative Molecular Group. The DNA methylation-based recurrence model performed well in adults (AUC = 0.83) but poorly in the Ped/AYA cohort (AUC = 0.57). However, retraining the model on only younger patients improved performance (AUC = 0.75). In addition, Ped/AYA tumors exhibited significantly fewer chromosomal alterations, including lower frequencies of 1p, 6q, and 14q loss (p<0.05). Taken together, these findings indicate that predominantly adult-trained methylation models underperform in younger meningioma patients due to both biological divergence and exclusion from training datasets. Our findings underscore the need for age-specific molecular tools to improve prognostication and support personalized care across the lifespan in neuro-oncology.